Search Results
Jul 13, 2026, 03:54 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with the Schall Law Firm
statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company's optimism related to the NHS-Galleri study was overstated, and ignored data suggesting its three-year
More news about: The Schall Law Firm
Jul 09, 2026, 09:00 ET INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- HBSS
9, 2026 /PRNewswire/ -- On February 20, 2026, GRAIL, Inc. shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jul 09, 2026, 08:04 ET Disrupting UK Private Care: Why Surgeons Shouldn't Spend Sundays Writing Invoices
the structure of UK private practice is the root of the problem. Most consultants still spend the bulk of their week in the National Health Service (NHS), where systems, staffing, and operational support are provided for them. But the moment they step into private practice, they become sole traders responsible
More news about: Disruption Interruption
Jul 09, 2026, 08:00 ET HemoScreen Now Deployed Across More Than One-Third of NHS Mental Health Trusts, Supporting a New Integrated Diagnostics Model in Psychiatric Healthcare
across more than 100 NHS mental health clinics within leading NHS organizations, including Oxford University Hospitals NHS Foundation Trust, South London and Maudsley NHS Foundation Trust, Kent and Medway NHS and Social Care Partnership Trust, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust,
More news about: PixCell Medical
Jul 08, 2026, 10:46 ET Global Medical Device Reprocessing Market to Register Sustainable Growth at a CAGR of ~8% by 2034 | DelveInsight
single-use medical products by 2045, positioning SUD reprocessing as a key strategy for achieving sustainability goals within the National Health Service (NHS) and supporting long-term demand. Meanwhile, France initiated a pilot program in 2024 to assess the economic feasibility of duodenoscope reprocessing,
More news about: DelveInsight Business Research, LLP
Jul 08, 2026, 10:11 ET Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
disclosed its NHS-Galleri trial failed to achieve its primary endpoint. Investors have until August 4, 2026 to seek lead plaintiff appointment.The Early OptimismIn May 2025, Grail announced positive top-line results from the prevalent screening round of its 140,000-participant NHS-Galleri
More news about: Levi & Korsinsky, LLP
Jul 07, 2026, 20:48 ET GRAIL, Inc. (GRAL) Securities Class Action Filed Following NHS-Galleri Trial Failure and $2.2 Billion Market Cap Loss -- HBSS
/PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jul 07, 2026, 08:00 ET INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead the Grail Class Action Lawsuit
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP
Jul 07, 2026, 06:36 ET GRAL Investment Deadline: GRAIL, Inc. Securities Fraud Class Action Focuses on Trial Results; Investors Notified of August 4 Court Deadline
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jul 06, 2026, 06:44 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 06, 2026, 03:00 ET MRX1 Successfully Delivered to Clinical Trial Site
PharmaAnanda Pharma is a UK pharmaceutical company providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University
More news about: Ananda Pharma Limited
Jul 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
action] On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On
More news about: Pomerantz LLP
Jul 02, 2026, 09:28 ET GRAL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
and the positive predictive value ("PPV") observed in the Pathfinder studies and in NHS-Galleri's top-line results as sources of confidence for its potential. Defendants further routinely touted the design of the NHS-Galleri and how three years were necessary to demonstrate the achievability of the primary
More news about: Faruqi & Faruqi, LLP
Jul 02, 2026, 09:00 ET GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
/PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jul 01, 2026, 10:07 ET GRAL DEADLINE: Levi & Korsinsky Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline
Time-Sensitive: Allegations Focus on Defendants' Refusal to Share Detailed NHS-Galleri Data, Potentially Concealing Adverse Trendlines From InvestorsNEW YORK, July 1, 2026 /PRNewswire/ -- Levi & Korsinsky,
More news about: Levi & Korsinsky, LLP
Jun 30, 2026, 16:30 ET NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION
NEW YORK, June 30, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on July 31,
More news about: Neuberger Berman
Jun 30, 2026, 06:23 ET $GRAL Notification: GRAIL, Inc. Accused of Misrepresentations about its Trial Results in Securities Fraud Class Action
implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test
More news about: Bleichmar Fonti & Auld LLP
Jun 29, 2026, 15:31 ET GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
/PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jun 28, 2026, 18:49 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL's NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial
More news about: THE ROSEN LAW FIRM, P. A.
Jun 25, 2026, 10:52 ET Northumbria Healthcare NHS Foundation Trust Continues to Deliver Outstanding Patient Care with Schneider Electric's EcoStruxure™ Data Centre solution
Supporting high-performing NHS servicesThe Trust provides health and care services to more than 500,000 people across Northumberland and North Tyneside. Covering around 2,500 square miles, it is the largest geographically in the UK and one of the highest performing NHS organisations, having been
More news about: Schneider Electric
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
action]On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On
More news about: Pomerantz LLP
Jun 25, 2026, 09:00 ET GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS
/PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased
More news about: Hagens Berman Sobol Shapiro LLP
Jun 25, 2026, 09:00 ET GRAIL Completes $110 Million Equity Financing With Samsung Entities
evaluation1-3. The Galleri test is backed by a robust clinical evidence program, with more than 380,000 participants across multiple studies, including the NHS-Galleri trial, the first and only randomized controlled trial for an MCED test. The Galleri test has delivered consistent performance across these studies.
More news about: GRAIL, Inc.
Jun 25, 2026, 09:00 ET ROYAL CARIBBEAN PARTNERS WITH ROALD DAHL'S MARVELLOUS CHILDREN'S CHARITY AHEAD OF "CHARLIE AND THE CHOCOLATE FACTORY" DEBUT ON LEGEND OF THE SEAS
fundraising moments across Legend's inaugural European season will help support the charity's network of more than 250 specialist nurses working across NHS Trusts, delivering coordinated care alongside emotional and financial support to families. "As a brand focused on creating memorable holidays
More news about: Royal Caribbean International
Jun 25, 2026, 07:10 ET GRAL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome; (ii) in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality; and (iii) the confidence
More news about: Robbins Geller Rudman & Dowd LLP